DaVita (NYSE:DVA) Price Target Raised to $224.00

DaVita (NYSE:DVA) had its target price increased by Barclays from $218.00 to $224.00 in a research report report published on Wednesday morning, Marketbeat.com reports. The brokerage currently has an equal weight rating on the stock.

Other equities research analysts have also issued research reports about the company. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. TD Cowen raised their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Truist Financial increased their price objective on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and raised their price objective for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $221.75.

DaVita Stock Up 1.5%

Shares of NYSE DVA opened at $183.39 on Wednesday. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The stock has a market cap of $11.70 billion, a price-to-earnings ratio of 15.01, a P/E/G ratio of 0.60 and a beta of 0.88. The company’s fifty day moving average is $218.43 and its 200-day moving average is $176.53.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts anticipate that DaVita will post 14.57 EPS for the current fiscal year.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.90% of the company’s stock.

Institutional Trading of DaVita

A number of hedge funds have recently made changes to their positions in DVA. Fifth Third Bancorp lifted its holdings in shares of DaVita by 831.4% during the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after buying an additional 34,287 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of DaVita by 27.4% in the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its position in DaVita by 63.5% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after acquiring an additional 33,394 shares during the period. LSV Asset Management raised its stake in DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after purchasing an additional 9,739 shares in the last quarter. Finally, M&T Bank Corp raised its stake in DaVita by 694.7% in the 4th quarter. M&T Bank Corp now owns 22,307 shares of the company’s stock worth $2,534,000 after purchasing an additional 19,500 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.